ProDGNE is a 3 year transnational pre-clinical research project which aims to develop an innovative therapeutic compound to treat GNE Myopathy (GNEM), an ultra rare muscle disease affecting young adults.

ProDGNE represents a unique joint collaboration among patients, European and Canadian experts in clinical GNE Myopathy, sialic acid, organic synthesis, and -OMIC technologies. 

The project is funded in the framework of the European Joint Programme on Rare Diseases (EJP RD) Joint Transnational Call 2020 "Pre-Clinical Research to Develop Effective Therapies for Rare Diseases".

ProDGNE receives funding from the European Commission (EC) under the Horizon 2020 EJP-COFUND action and the following funding organisations: 

• FCT - Foundation for Science and Technology (Portugal)
• DFG - German Research Foundation (Germany); 
• MUR - Ministry of Universities and Research (Italy)
• CIHR - Canadian Institutes of Health Research – Institute of Genetics (Canada) 
• INSERM (France)

This project has received funding from the European Union's Horizon 2020 research and innovation programme under the EJP RD COFUND-EJP N 825575